AbbVie (ABBV) Q2 2026 (USD): Adj. EPS 3.65 (exp. 3.60), Revenue 17.0bln (exp. 16.8bln)

• Sees FY adj. EPS at 13.87-14.07 (exp. 14.06). Includes a 0.14/shr Dilutive Impact Related to the Proposed Acquisition of Apogee Therapeutics (APOG), Which is Anticipated to Close in the Third Quarter of 2026; Includes an Unfavorable Impact of 0.58/shr Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Second Quarter 2026 

A headline beat of this size on both lines, with full-year guidance bracketing the consensus number, is the kind of print that typically resolves as a neutral-to-modestly-positive open rather than a re-rating event; the stock's direction has historically been set by the guidance raise question and by pipeline commentary rather than by the quarter itself. The two dilutive items disclosed are the more informative part: the acquired IPR&D and milestone charge is routine for this name, which has made a pattern of absorbing such charges through the year and then adjusting the guide at later quarters, so the tell is whether the ex-items trajectory still implies a raise by year-end. The deal-related dilution puts the pending acquisition on the calendar as the next catalyst, and large-cap pharma bolt-ons of this kind have tended to be received on the strength of the strategic fit and the revenue bridge rather than the near-term per-share cost. What follows the print in this peer set is usually a call-driven move on aesthetics commentary and immunology franchise trajectory, the two lines that have carried the narrative since the loss of exclusivity on its legacy blockbuster. The bar having been a guide that merely brackets consensus, the sequence to watch is management's language on whether the upper end reflects conservatism or genuine visibility.